中药对肺纯磨玻璃结节临床特征和生物学标志物的影响:一项多中心随机三盲对照试验的研究方案

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Frontiers in Medicine Pub Date : 2025-09-19 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1663135
Shi-Yan Tan, Qiong Ma, Qian Wang, Tao-Yu Wu, Zi-Fan Wang, Zong-Yi Mao, Chong Xiao, Chuan Zheng, Feng-Ming You, Yi-Feng Ren
{"title":"中药对肺纯磨玻璃结节临床特征和生物学标志物的影响:一项多中心随机三盲对照试验的研究方案","authors":"Shi-Yan Tan, Qiong Ma, Qian Wang, Tao-Yu Wu, Zi-Fan Wang, Zong-Yi Mao, Chong Xiao, Chuan Zheng, Feng-Ming You, Yi-Feng Ren","doi":"10.3389/fmed.2025.1663135","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The widespread use of chest computed tomography (CT) screening has led to more frequent detection of pure ground-glass nodules (pGGNs). A subset of pGGNs carries a potential risk of malignant transformation. However, the current management strategy for stable pGGNs predominantly involves surveillance, with a notable absence of effective intervention strategies. Traditional Chinese medicine (TCM), as an adjunctive therapy, offers considerable promise. Preclinical studies indicate that Chuanjie Granules (CJG), a TCM compound formulation, may have potential benefits in reducing the size of pGGNs. However, there is a lack of strong evidence from large-scale randomized controlled trials. Consequently, this study aims to evaluate the clinical effectiveness and safety of CJG for pGGNs through a well-designed clinical trial and explore its mechanisms of action.</p><p><strong>Methods: </strong>This study is a prospective, randomized, triple-blind, placebo-controlled, multicenter clinical trial designed to enroll 172 patients who have been radiologically diagnosed with pGGNs. Participants will be randomly allocated in a 1:1 ratio to receive either CJG or placebo, both with standard health education. The intervention lasts 3 months with participants receiving either CJG or a placebo, followed by a 1-year observational period after treatment. The primary outcome is the change in pGGN maximum diameter, while secondary outcomes include nodule reduction rate, density changes, malignancy risk, and patient-reported outcomes. The study will also use 16S rRNA gene sequencing and gas chromatography-mass spectrometry-based metabolomics to examine oral and gut microbiota and explore microbial-metabolic mechanisms.</p><p><strong>Discussion: </strong>This study aims to rigorously assess the efficacy and safety of CJG and explore its mechanism of action in the intervention of pGGNs through a randomized controlled trial. Positive outcomes are anticipated to furnish the first high-quality evidence-based medical support for the use of TCM in the early intervention of pGGNs, thereby potentially enhancing clinical decision-making processes.</p><p><strong>Clinical trial registration: </strong>http://itmctr.ccebtcm.org.cn/, identifier ITMCTR2025001413.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1663135"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491048/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of herbal medicine on clinical characteristics and biological markers in pulmonary pure ground-glass nodules: study protocol for a multicenter randomized triple-blind controlled trial.\",\"authors\":\"Shi-Yan Tan, Qiong Ma, Qian Wang, Tao-Yu Wu, Zi-Fan Wang, Zong-Yi Mao, Chong Xiao, Chuan Zheng, Feng-Ming You, Yi-Feng Ren\",\"doi\":\"10.3389/fmed.2025.1663135\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The widespread use of chest computed tomography (CT) screening has led to more frequent detection of pure ground-glass nodules (pGGNs). A subset of pGGNs carries a potential risk of malignant transformation. However, the current management strategy for stable pGGNs predominantly involves surveillance, with a notable absence of effective intervention strategies. Traditional Chinese medicine (TCM), as an adjunctive therapy, offers considerable promise. Preclinical studies indicate that Chuanjie Granules (CJG), a TCM compound formulation, may have potential benefits in reducing the size of pGGNs. However, there is a lack of strong evidence from large-scale randomized controlled trials. Consequently, this study aims to evaluate the clinical effectiveness and safety of CJG for pGGNs through a well-designed clinical trial and explore its mechanisms of action.</p><p><strong>Methods: </strong>This study is a prospective, randomized, triple-blind, placebo-controlled, multicenter clinical trial designed to enroll 172 patients who have been radiologically diagnosed with pGGNs. Participants will be randomly allocated in a 1:1 ratio to receive either CJG or placebo, both with standard health education. The intervention lasts 3 months with participants receiving either CJG or a placebo, followed by a 1-year observational period after treatment. The primary outcome is the change in pGGN maximum diameter, while secondary outcomes include nodule reduction rate, density changes, malignancy risk, and patient-reported outcomes. The study will also use 16S rRNA gene sequencing and gas chromatography-mass spectrometry-based metabolomics to examine oral and gut microbiota and explore microbial-metabolic mechanisms.</p><p><strong>Discussion: </strong>This study aims to rigorously assess the efficacy and safety of CJG and explore its mechanism of action in the intervention of pGGNs through a randomized controlled trial. Positive outcomes are anticipated to furnish the first high-quality evidence-based medical support for the use of TCM in the early intervention of pGGNs, thereby potentially enhancing clinical decision-making processes.</p><p><strong>Clinical trial registration: </strong>http://itmctr.ccebtcm.org.cn/, identifier ITMCTR2025001413.</p>\",\"PeriodicalId\":12488,\"journal\":{\"name\":\"Frontiers in Medicine\",\"volume\":\"12 \",\"pages\":\"1663135\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491048/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fmed.2025.1663135\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1663135","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:胸部计算机断层扫描(CT)筛查的广泛使用导致纯磨玻璃结节(pggn)的检测频率更高。pggn的一个子集具有恶性转化的潜在风险。然而,目前稳定的pggn的管理策略主要涉及监测,明显缺乏有效的干预策略。中医作为一种辅助疗法,提供了相当大的前景。临床前研究表明,中药复方川芎颗粒剂(CJG)可能具有降低pggn大小的潜在益处。然而,缺乏大规模随机对照试验的有力证据。因此,本研究旨在通过精心设计的临床试验,评估CJG治疗pggn的临床有效性和安全性,并探讨其作用机制。方法:本研究是一项前瞻性、随机、三盲、安慰剂对照、多中心临床试验,设计入组172例经放射学诊断为pggn的患者。参与者将以1:1的比例随机分配,接受CJG或安慰剂,两者都有标准的健康教育。干预持续3 个月,参与者接受CJG或安慰剂,治疗后随访1年观察期。主要转归是pGGN最大直径的变化,次要转归包括结节缩小率、密度变化、恶性风险和患者报告的转归。该研究还将使用16S rRNA基因测序和基于气相色谱-质谱的代谢组学来检测口腔和肠道微生物群,并探索微生物代谢机制。讨论:本研究旨在通过随机对照试验,严格评估CJG对pggn的疗效和安全性,探讨其干预pggn的作用机制。积极的结果预计将为中医药在pggn早期干预中的应用提供第一个高质量的循证医学支持,从而有可能提高临床决策过程。临床试验注册:http://itmctr.ccebtcm.org.cn/,标识符ITMCTR2025001413。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effects of herbal medicine on clinical characteristics and biological markers in pulmonary pure ground-glass nodules: study protocol for a multicenter randomized triple-blind controlled trial.

Background: The widespread use of chest computed tomography (CT) screening has led to more frequent detection of pure ground-glass nodules (pGGNs). A subset of pGGNs carries a potential risk of malignant transformation. However, the current management strategy for stable pGGNs predominantly involves surveillance, with a notable absence of effective intervention strategies. Traditional Chinese medicine (TCM), as an adjunctive therapy, offers considerable promise. Preclinical studies indicate that Chuanjie Granules (CJG), a TCM compound formulation, may have potential benefits in reducing the size of pGGNs. However, there is a lack of strong evidence from large-scale randomized controlled trials. Consequently, this study aims to evaluate the clinical effectiveness and safety of CJG for pGGNs through a well-designed clinical trial and explore its mechanisms of action.

Methods: This study is a prospective, randomized, triple-blind, placebo-controlled, multicenter clinical trial designed to enroll 172 patients who have been radiologically diagnosed with pGGNs. Participants will be randomly allocated in a 1:1 ratio to receive either CJG or placebo, both with standard health education. The intervention lasts 3 months with participants receiving either CJG or a placebo, followed by a 1-year observational period after treatment. The primary outcome is the change in pGGN maximum diameter, while secondary outcomes include nodule reduction rate, density changes, malignancy risk, and patient-reported outcomes. The study will also use 16S rRNA gene sequencing and gas chromatography-mass spectrometry-based metabolomics to examine oral and gut microbiota and explore microbial-metabolic mechanisms.

Discussion: This study aims to rigorously assess the efficacy and safety of CJG and explore its mechanism of action in the intervention of pGGNs through a randomized controlled trial. Positive outcomes are anticipated to furnish the first high-quality evidence-based medical support for the use of TCM in the early intervention of pGGNs, thereby potentially enhancing clinical decision-making processes.

Clinical trial registration: http://itmctr.ccebtcm.org.cn/, identifier ITMCTR2025001413.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信